- Home
- IBRX vs TRIP Comparison
IBRX vs TRIP Comparison
Compare IBRX & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- TRIP
- Stock Information
- Founded
- IBRX 2014
- TRIP 2000
- Country
- IBRX United States
- TRIP United States
- Employees
- IBRX N/A
- TRIP N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- TRIP Computer Software: Programming Data Processing
- Sector
- IBRX Health Care
- TRIP Technology
- Exchange
- IBRX Nasdaq
- TRIP Nasdaq
- Market Cap
- IBRX 2.3B
- TRIP 2.1B
- IPO Year
- IBRX N/A
- TRIP 2011
- Fundamental
- Price
- IBRX $2.53
- TRIP $15.75
- Analyst Decision
- IBRX Strong Buy
- TRIP Hold
- Analyst Count
- IBRX 6
- TRIP 9
- Target Price
- IBRX $9.83
- TRIP $17.03
- AVG Volume (30 Days)
- IBRX 10.3M
- TRIP 2.9M
- Earning Date
- IBRX 11-11-2025
- TRIP 11-05-2025
- Dividend Yield
- IBRX N/A
- TRIP N/A
- EPS Growth
- IBRX N/A
- TRIP 165.58
- EPS
- IBRX N/A
- TRIP 0.46
- Revenue
- IBRX $56,600,000.00
- TRIP $1,870,000,000.00
- Revenue This Year
- IBRX $629.94
- TRIP $7.36
- Revenue Next Year
- IBRX $109.91
- TRIP $7.41
- P/E Ratio
- IBRX N/A
- TRIP $34.01
- Revenue Growth
- IBRX 4227.22
- TRIP 3.03
- 52 Week Low
- IBRX $1.83
- TRIP $10.43
- 52 Week High
- IBRX $7.48
- TRIP $20.16
- Technical
- Relative Strength Index (RSI)
- IBRX 47.77
- TRIP 38.03
- Support Level
- IBRX $2.42
- TRIP $15.31
- Resistance Level
- IBRX $2.75
- TRIP $17.03
- Average True Range (ATR)
- IBRX 0.13
- TRIP 0.87
- MACD
- IBRX -0.01
- TRIP -0.26
- Stochastic Oscillator
- IBRX 22.88
- TRIP 8.76
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).